Join us for the annual Excellence in Health Journalism Awards presentation, recognising and celebrating journalists who have produced outstanding work that contributes to quality journalism on topics primarily concerned with, or related to, the health sector.

The event will feature a distinguished guest speaker Professor Dame Sue Hill DBE, Chief Scientific Officer for England and Senior Responsible Officer for Genomics in the NHS.

Professor Dame Sue Hill DBE will deliver an oration titled “Scaling Clinical Genomics: Lessons from the NHS for Australia”.

Professor Dame Sue Hill DBE

Professor Dame Sue Hill DBE, will explore “Scaling Clinical Genomics: Lessons from the NHS for Australia.”

How can Australia turn the promise of genomics into better, more equitable care for patients?

Professor Dame Sue Hill, Chief Scientific Officer for England, will share lessons from taking the NHS’s landmark 100,000 Genomes Project into a nationwide genomic medicine service. Drawing on her experience leading this transformation, she will explore how genomics is improving diagnosis and informing more personalised treatment, particularly for people with cancer and rare diseases.

As Australia moves towards wider use of genomics in routine healthcare, Dame Sue will discuss the infrastructure and changes needed to deliver services at scale, the challenges still to be resolved, and what England’s experience can teach us about translating scientific advances into practical benefits for patients.

BIO

Professor Dame Sue Hill DBE is Chief Scientific Officer for England and Senior Responsible Officer for Genomics in the NHS. A respiratory scientist by background, she provides scientific leadership across the health system and professional leadership for the healthcare science workforce.

Dame Sue led the NHS contribution to the 100,000 Genomes Project and the introduction of the nationwide NHS Genomic Medicine Service, helping bring genomic testing into routine patient car She 

was appointed a Dame Commander of the Order of the British Empire in 2018 for services to the NHS and genomic medicine.

Award Partners

Rare Cancers Australia Ltd.

Rare Cancers Australia (RCA) is a national not-for-profit organisation dedicated to improving outcomes for people living with rare and less common cancers. Through specialist cancer navigation, advocacy and system reform, RCA works to ensure people receive the right support, at the right time, throughout their cancer journey.

Omico

Omico is changing the way we fight cancer.

An independent, not-for-profit, organisation, Omico is providing Australians with equitable, accelerated access to cutting-edge, proven precision oncology. Our role is to translate the latest scientific innovations into meaningful advances in clinical care, health policy and system reform, ensuring science delivers real-world benefit for patients. We unite Australia’s leading cancer institutes, researchers, clinicians, industry partners, advocacy groups and government to facilitate a new way to tackle our most challenging cancers. By harnessing a nationwide network of expertise, infrastructure and resources, we aim to improve outcomes for Australian cancer patients. By fast tracking molecular and genomic profiling, biomarker-led clinical trials and patient enrolment across the country, Omico is enabling access to next-generation treatments and preventive strategies for those who need them most.

Join us for the annual Excellence in Health Journalism Awards presentation, recognising and celebrating journalists who have produced outstanding work that contributes to quality journalism on topics primarily concerned with, or related to, the health sector.

The event will feature a distinguished guest speaker Professor Dame Sue Hill DBE, Chief Scientific Officer for England and Senior Responsible Officer for Genomics in the NHS.

Professor Dame Sue Hill DBE will deliver an oration titled “Scaling Clinical Genomics: Lessons from the NHS for Australia”.

Professor Dame Sue Hill DBE

Professor Dame Sue Hill DBE, will explore “Scaling Clinical Genomics: Lessons from the NHS for Australia.”

How can Australia turn the promise of genomics into better, more equitable care for patients?

Professor Dame Sue Hill, Chief Scientific Officer for England, will share lessons from taking the NHS’s landmark 100,000 Genomes Project into a nationwide genomic medicine service. Drawing on her experience leading this transformation, she will explore how genomics is improving diagnosis and informing more personalised treatment, particularly for people with cancer and rare diseases.

As Australia moves towards wider use of genomics in routine healthcare, Dame Sue will discuss the infrastructure and changes needed to deliver services at scale, the challenges still to be resolved, and what England’s experience can teach us about translating scientific advances into practical benefits for patients.

BIO

Professor Dame Sue Hill DBE is Chief Scientific Officer for England and Senior Responsible Officer for Genomics in the NHS. A respiratory scientist by background, she provides scientific leadership across the health system and professional leadership for the healthcare science workforce.

Dame Sue led the NHS contribution to the 100,000 Genomes Project and the introduction of the nationwide NHS Genomic Medicine Service, helping bring genomic testing into routine patient car She 

was appointed a Dame Commander of the Order of the British Empire in 2018 for services to the NHS and genomic medicine.

Award Partners

Rare Cancers Australia Ltd.

Rare Cancers Australia (RCA) is a national not-for-profit organisation dedicated to improving outcomes for people living with rare and less common cancers. Through specialist cancer navigation, advocacy and system reform, RCA works to ensure people receive the right support, at the right time, throughout their cancer journey.

Omico

Omico is changing the way we fight cancer.

An independent, not-for-profit, organisation, Omico is providing Australians with equitable, accelerated access to cutting-edge, proven precision oncology. Our role is to translate the latest scientific innovations into meaningful advances in clinical care, health policy and system reform, ensuring science delivers real-world benefit for patients. We unite Australia’s leading cancer institutes, researchers, clinicians, industry partners, advocacy groups and government to facilitate a new way to tackle our most challenging cancers. By harnessing a nationwide network of expertise, infrastructure and resources, we aim to improve outcomes for Australian cancer patients. By fast tracking molecular and genomic profiling, biomarker-led clinical trials and patient enrolment across the country, Omico is enabling access to next-generation treatments and preventive strategies for those who need them most.